{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:33:00Z","timestamp":1792204380132,"version":"4.4.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,1,20]],"date-time":"2016-01-20T00:00:00Z","timestamp":1453248000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s00280-016-2959-0","type":"journal-article","created":{"date-parts":[[2016,1,19]],"date-time":"2016-01-19T22:20:21Z","timestamp":1453242021000},"page":"895-903","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["The selective estrogen receptor modulators in breast cancer prevention"],"prefix":"10.1007","volume":"77","author":[{"given":"Fangxuan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinli","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juntian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,20]]},"reference":[{"issue":"3","key":"2959_CR1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/jamainternmed.2013.2127","volume":"173","author":"JS Mandelblatt","year":"2013","unstructured":"Mandelblatt JS, Tosteson AN, van Ravesteyn NT (2013) Costs, evidence, and value in the Medicare program: the challenges of technology innovation in breast cancer prevention and control. JAMA Intern Med 173(3):227\u2013228","journal-title":"JAMA Intern Med"},{"issue":"1","key":"2959_CR2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3322\/caac.21203","volume":"64","author":"C DeSantis","year":"2014","unstructured":"DeSantis C et al (2014) Breast cancer statistics, 2013. CA Cancer J Clin 64(1):52\u201362","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"2959_CR3","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1056\/NEJMra050776","volume":"354","author":"JD Yager","year":"2006","unstructured":"Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354(3):270\u2013282","journal-title":"N Engl J Med"},{"issue":"11","key":"2959_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/dju305","volume":"106","author":"M Garcia-Closas","year":"2014","unstructured":"Garcia-Closas M, Gunsoy NB, Chatterjee N (2014) Combined associations of genetic and environmental risk factors: implications for prevention of breast cancer. J Natl Cancer Inst 106(11):1\u20136","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2959_CR5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s12609-012-0082-8","volume":"4","author":"L Reimers","year":"2012","unstructured":"Reimers L, Crew KD (2012) Tamoxifen versus raloxifene versus exemestane for chemoprevention. Curr Breast Cancer Rep 4(3):207\u2013215","journal-title":"Curr Breast Cancer Rep"},{"issue":"18","key":"2959_CR6","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher B et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18):1371\u20131388","journal-title":"J Natl Cancer Inst"},{"issue":"22","key":"2959_CR7","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/jnci\/dji372","volume":"97","author":"B Fisher","year":"2005","unstructured":"Fisher B et al (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97(22):1652\u20131662","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2959_CR8","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/jnci\/95.2.160","volume":"95","author":"U Veronesi","year":"2003","unstructured":"Veronesi U et al (2003) Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 95(2):160\u2013165","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"2959_CR9","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/jnci\/djk154","volume":"99","author":"U Veronesi","year":"2007","unstructured":"Veronesi U et al (2007) Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 99(9):727\u2013737","journal-title":"J Natl Cancer Inst"},{"issue":"9122","key":"2959_CR10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0140-6736(98)85012-5","volume":"352","author":"T Powles","year":"1998","unstructured":"Powles T et al (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352(9122):98\u2013101","journal-title":"Lancet"},{"issue":"4","key":"2959_CR11","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jnci\/djk050","volume":"99","author":"TJ Powles","year":"2007","unstructured":"Powles TJ et al (2007) Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99(4):283\u2013290","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2959_CR12","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/jnci\/djk049","volume":"99","author":"J Cuzick","year":"2007","unstructured":"Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A (2007) Long-term results of tamoxifen prophylaxis for breast cancer\u201496-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99(4):272\u2013282","journal-title":"J Natl Cancer Inst"},{"issue":"9336","key":"2959_CR13","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(02)09962-2","volume":"360","author":"J Cuzick","year":"2002","unstructured":"Cuzick J et al (2002) First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360(9336):817\u2013824","journal-title":"Lancet"},{"issue":"1","key":"2959_CR14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(14)71171-4","volume":"16","author":"J Cuzick","year":"2015","unstructured":"Cuzick J et al (2015) Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 16(1):67\u201375","journal-title":"Lancet Oncol"},{"issue":"12","key":"2959_CR15","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/jama.279.12.922","volume":"279","author":"KE Malone","year":"1998","unstructured":"Malone KE et al (1998) BRCA1 mutations and breast cancer in the general population: analyses in women before age 35\u00a0years and in women before age 45\u00a0years with first-degree family history. JAMA 279(12):922\u2013929","journal-title":"JAMA"},{"issue":"18","key":"2959_CR16","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.286.18.2251","volume":"286","author":"MC King","year":"2001","unstructured":"King MC et al (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286(18):2251\u20132256","journal-title":"JAMA"},{"issue":"2","key":"2959_CR17","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.canlet.2006.05.003","volume":"247","author":"Z Kote-Jarai","year":"2007","unstructured":"Kote-Jarai Z et al (2007) BRCA1\/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial. Cancer Lett 247(2):259\u2013265","journal-title":"Cancer Lett"},{"issue":"4","key":"2959_CR18","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s12282-015-0619-6","volume":"22","author":"L Xu","year":"2015","unstructured":"Xu L et al (2015) Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis. Breast Cancer 22(4):327\u2013334","journal-title":"Breast Cancer"},{"issue":"25","key":"2959_CR19","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1200\/JCO.2012.47.8313","volume":"31","author":"KA Phillips","year":"2013","unstructured":"Phillips KA et al (2013) Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol 31(25):3091\u20133099","journal-title":"J Clin Oncol"},{"issue":"4","key":"2959_CR20","doi-asserted-by":"crossref","first-page":"365","DOI":"10.6004\/jnccn.2013.0050","volume":"11","author":"F Detterbeck","year":"2013","unstructured":"Detterbeck F, Tanoue L, Reid A (2013) National comprehensive cancer network. J Natl Compr Canc Netw 11(4):365\u2013366","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"2959_CR21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2217\/fon.13.278","volume":"10","author":"KA Phillips","year":"2014","unstructured":"Phillips KA, Lindeman GJ (2014) Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: Is there a role for tamoxifen? Future Oncol 10(4):499\u2013502","journal-title":"Future Oncol"},{"key":"2959_CR22","first-page":"59","volume":"6","author":"P Advani","year":"2014","unstructured":"Advani P, Moreno-Aspitia A (2014) Current strategies for the prevention of breast cancer. Breast Cancer (Dove Med Press) 6:59\u201371","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"9354","key":"2959_CR23","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0140-6736(03)12342-2","volume":"361","author":"J Cuzick","year":"2003","unstructured":"Cuzick J et al (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361(9354):296\u2013300","journal-title":"Lancet"},{"issue":"9114","key":"2959_CR24","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","volume":"351","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1998","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351(9114):1451\u20131467","journal-title":"Lancet"},{"key":"2959_CR25","first-page":"197","volume-title":"The scientific bases of cancer chemoprevention","author":"C Maltoni","year":"1996","unstructured":"Maltoni C et al (1996) Experimental results on the chemopreventive and side effects of tamoxifen using a human-equivalent animal model. In: Maltoni C, Soffritti M, Davis W (eds) The scientific bases of cancer chemoprevention. Elsevier Science BV, Amsterdam, pp 197\u2013207"},{"issue":"19","key":"2959_CR26","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/jnci\/90.19.1461","volume":"90","author":"A Decensi","year":"1998","unstructured":"Decensi A et al (1998) Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst 90(19):1461\u20131467","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"2959_CR27","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/jnci\/95.11.779","volume":"95","author":"A Decensi","year":"2003","unstructured":"Decensi A et al (2003) A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 95(11):779\u2013790","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"2959_CR28","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S0959-8049(02)00530-0","volume":"39","author":"GR Lima de","year":"2003","unstructured":"de Lima GR et al (2003) Effects of low dose tamoxifen on normal breast tissue from premenopausal women. Eur J Cancer 39(7):891\u2013898","journal-title":"Eur J Cancer"},{"issue":"27","key":"2959_CR29","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1200\/JCO.2006.09.4318","volume":"25","author":"A Decensi","year":"2007","unstructured":"Decensi A et al (2007) Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users. J Clin Oncol 25(27):4201\u20134209","journal-title":"J Clin Oncol"},{"key":"2959_CR30","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/978-3-642-55647-0_10","volume":"163","author":"A Decensi","year":"2003","unstructured":"Decensi A, Galli A, Veronesi U (2003) HRT opposed to low-dose tamoxifen (HOT study): rationale and design. Recent Results Cancer Res 163:104\u2013111 discussion 264-6","journal-title":"Recent Results Cancer Res"},{"issue":"11","key":"2959_CR31","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1093\/annonc\/mdt244","volume":"24","author":"A DeCensi","year":"2013","unstructured":"DeCensi A et al (2013) A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study. Ann Oncol 24(11):2753\u20132760","journal-title":"Ann Oncol"},{"issue":"2","key":"2959_CR32","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1200\/JCO.2000.18.2.284","volume":"18","author":"TJ Smith","year":"2000","unstructured":"Smith TJ, Hillner BE (2000) Tamoxifen should be cost-effective in reducing breast cancer risk in high-risk women. J Clin Oncol 18(2):284\u2013286","journal-title":"J Clin Oncol"},{"issue":"1","key":"2959_CR33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1200\/JCO.20.1.9","volume":"20","author":"D Hershman","year":"2002","unstructured":"Hershman D et al (2002) Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis. J Clin Oncol 20(1):9\u201316","journal-title":"J Clin Oncol"},{"issue":"1","key":"2959_CR34","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1056\/NEJMsr1407164","volume":"372","author":"LC Hartmann","year":"2015","unstructured":"Hartmann LC et al (2015) A typical hyperplasia of the breast\u2014risk assessment and management options. N Engl J Med 372(1):78\u201389","journal-title":"N Engl J Med"},{"issue":"3","key":"2959_CR35","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/01.AOG.0000133481.74113.f3","volume":"104","author":"S Cykert","year":"2004","unstructured":"Cykert S, Phifer N, Hansen C (2004) Tamoxifen for breast cancer prevention: a framework for clinical decisions. Obstet Gynecol 104(3):433\u2013442","journal-title":"Obstet Gynecol"},{"issue":"5","key":"2959_CR36","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/cncr.22075","volume":"107","author":"J Melnikow","year":"2006","unstructured":"Melnikow J et al (2006) Chemoprevention: drug pricing and mortality: the case of tamoxifen. Cancer 107(5):950\u2013958","journal-title":"Cancer"},{"issue":"1","key":"2959_CR37","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1467-842X.2003.tb00377.x","volume":"27","author":"SD Eckermann","year":"2003","unstructured":"Eckermann SD et al (2003) The benefits and costs of tamoxifen for breast cancer prevention. Aust N Z J Public Health 27(1):34\u201340","journal-title":"Aust N Z J Public Health"},{"issue":"2","key":"2959_CR38","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/sj.bjc.6604869","volume":"100","author":"M Kondo","year":"2009","unstructured":"Kondo M, Hoshi SL, Toi M (2009) Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan. Br J Cancer 100(2):281\u2013290","journal-title":"Br J Cancer"},{"issue":"8","key":"2959_CR39","doi-asserted-by":"crossref","first-page":"719","DOI":"10.6004\/jnccn.2007.0073","volume":"5","author":"TB Bevers","year":"2007","unstructured":"Bevers TB (2007) The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women. J Natl Compr Canc Netw 5(8):719\u2013724","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"2959_CR40","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1006478317173","volume":"65","author":"JA Cauley","year":"2001","unstructured":"Cauley JA et al (2001) Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65(2):125\u2013134","journal-title":"Breast Cancer Res Treat"},{"issue":"23","key":"2959_CR41","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jnci\/djh319","volume":"96","author":"S Martino","year":"2004","unstructured":"Martino S et al (2004) Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96(23):1751\u20131761","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2959_CR42","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","volume":"355","author":"E Barrett-Connor","year":"2006","unstructured":"Barrett-Connor E et al (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355(2):125\u2013137","journal-title":"N Engl J Med"},{"issue":"23","key":"2959_CR43","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","volume":"295","author":"VG Vogel","year":"2006","unstructured":"Vogel VG et al (2006) Effects of tamoxifen versus raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295(23):2727\u20132741","journal-title":"JAMA"},{"issue":"6","key":"2959_CR44","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/1940-6207.CAPR-10-0076","volume":"3","author":"VG Vogel","year":"2010","unstructured":"Vogel VG et al (2010) Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila) 3(6):696\u2013706","journal-title":"Cancer Prev Res (Phila)"},{"issue":"6","key":"2959_CR45","first-page":"996","volume":"98","author":"K Armstrong","year":"2001","unstructured":"Armstrong K et al (2001) Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk. Obstet Gynecol 98(6):996\u20131003","journal-title":"Obstet Gynecol"},{"issue":"8","key":"2959_CR46","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJMoa0808692","volume":"362","author":"SR Cummings","year":"2010","unstructured":"Cummings SR et al (2010) Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 362(8):686\u2013696","journal-title":"N Engl J Med"},{"issue":"22","key":"2959_CR47","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/jnci\/djq415","volume":"102","author":"AZ LaCroix","year":"2010","unstructured":"LaCroix AZ et al (2010) Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst 102(22):1706\u20131715","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2959_CR48","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/jbmr.191","volume":"26","author":"SR Cummings","year":"2011","unstructured":"Cummings SR et al (2011) Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res 26(2):397\u2013404","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2959_CR49","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10549-012-2041-5","volume":"134","author":"TJ Powles","year":"2012","unstructured":"Powles TJ et al (2012) Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene. Breast Cancer Res Treat 134(1):299\u2013306","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"2959_CR50","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1517\/14740338.2015.1014799","volume":"14","author":"AJ Ellis","year":"2015","unstructured":"Ellis AJ et al (2015) Selective estrogen receptor modulators in clinical practice: a safety overview. Expert Opin Drug Saf 14(6):921\u2013934","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"2959_CR51","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1124\/mol.111.072249","volume":"80","author":"JS Lewis-Wambi","year":"2011","unstructured":"Lewis-Wambi JS et al (2011) The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor alpha and cyclin D1. Mol Pharmacol 80(4):610\u2013620","journal-title":"Mol Pharmacol"},{"issue":"1","key":"2959_CR52","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00198-011-1691-1","volume":"23","author":"SL Silverman","year":"2012","unstructured":"Silverman SL et al (2012) Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 23(1):351\u2013363","journal-title":"Osteoporos Int"},{"issue":"9880","key":"2959_CR53","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0140-6736(13)60140-3","volume":"381","author":"J Cuzick","year":"2013","unstructured":"Cuzick J et al (2013) Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 381(9880):1827\u20131834","journal-title":"Lancet"},{"issue":"19","key":"2959_CR54","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1200\/JCO.2008.20.5179","volume":"27","author":"K Visvanathan","year":"2009","unstructured":"Visvanathan K et al (2009) American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27(19):3235\u20133258","journal-title":"J Clin Oncol"},{"issue":"10","key":"2959_CR55","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.6004\/jnccn.2010.0083","volume":"8","author":"TB Bevers","year":"2010","unstructured":"Bevers TB et al (2010) Breast cancer risk reduction. J Natl Compr Canc Netw 8(10):1112\u20131146","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"2959_CR56","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s10549-012-2089-2","volume":"134","author":"EA Waters","year":"2012","unstructured":"Waters EA et al (2012) Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Res Treat 134(2):875\u2013880","journal-title":"Breast Cancer Res Treat"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-2959-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-016-2959-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-2959-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T06:07:40Z","timestamp":1559023660000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-016-2959-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,20]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["2959"],"URL":"https:\/\/doi.org\/10.1007\/s00280-016-2959-0","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,20]]}}}